KaloBios Pledges to Avoid ‘Price-Gouging’ in the Future

Source: International Business Times

Apr 12, 2016

KaloBios Pharmaceuticals, a California-based biotechnology company focusing on treatments for conditions such as Chagas disease, made a public pledge this week to be more transparent on drug pricing moving forward. According to International Business Times, the company swore it would “not engage in aggressive pricing or ‘price-gouging.’”

KaloBios was the focus of much criticism last year due to the direction of its former CEO Martin Shkreli, who became infamous after he increased the price of a medication by 5,456 percent.

At the time, Schkreli─a former hedge fund manager─was also serving as CEO of Turing Pharmaceuticals.

“Our new pricing model is a commitment to define and develop transparent, responsible pricing for the products we hope to bring to patients in the future,”  KaloBios Chairman and CEO Cameron Durrant said in a statement. “Drug pricing is a big concern for all stakeholders in healthcare. We believe that our approach balances the needs of key stakeholders, including patients, clinicians, payers, [nongovernmental organizations], investors, policymakers and advocacy groups.”

KaloBios fired Shkreli on Dec. 17, 2015, the same day he was arrested on securities fraud charges.

You can read the full release from KaloBios here. 


Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments